# Pyridostigmine as Immunomodulator in People Living With HIV

> **NCT03312244** · PHASE2 · SUSPENDED · sponsor: **Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran** · enrollment: 60 (estimated)

## Conditions studied

- HIV-1-infection
- CD4+ T Lymphocytopenia
- Immune Deficiency
- Immuno-senescence

## Interventions

- **DRUG:** Pyridostigmine Bromide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03312244
- **Lead sponsor:** Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2019-07-01
- **Primary completion:** 2021-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** Due to COVID-19, effective 3/19/2020 recruitment is halted until further notice
- **Last updated:** 2020-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312244, "Pyridostigmine as Immunomodulator in People Living With HIV". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03312244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*